Dr. Daniel B. Flora, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
- Medicare participating
At a glance
- Medical school
- Wright State University Boonshoft School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 212
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: Wright State University Boonshoft School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
KY license 46980 · IN license 01073548A · OH license 35.097362
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- St Elizabeth Edgewood Edgewood, KY
- St Elizabeth Florence Florence, KY
- St Elizabeth Ft Thomas Fort Thomas, KY
- St Elizabeth Dearborn Hospital Lawrenceburg, IN
Medical groups
- St Elizabeth Medical Center, Inc (187 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 212
- Services billed
- 840
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 466 | 175 |
| Established patient office or other outpatient visit, 40-54 minutes | 54 | 30 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 36 | 25 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 21 | 21 |
| New patient office or other outpatient visit, 60-74 minutes | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Eliquis (apixaban) Other prescribers in Edgewood, KY | 86 |
| Letrozole Other prescribers in Edgewood, KY | 61 |
| Anastrozole Other prescribers in Edgewood, KY | 60 |
| Prednisone Other prescribers in Edgewood, KY | 49 |
| Prochlorperazine Maleate Other prescribers in Edgewood, KY | 46 |
| Dexamethasone Other prescribers in Edgewood, KY | 44 |
| Gabapentin Other prescribers in Edgewood, KY | 35 |
| Hydroxyurea Other prescribers in Edgewood, KY | 32 |
| Levothyroxine Sodium Other prescribers in Edgewood, KY | 31 |
| Abiraterone Acetate | 31 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $19.68 in total to this clinician.
| Regeneron Healthcare Solutions, Inc. | $19.68 |
|---|
| Food and Beverage | $19.68 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $304,213 in research payments for these studies, mostly to the institutions running them.
- CAMBRIA-1 A Phase III, Open-Label,Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) vs Standard Endocrine …
AstraZeneca UK Limited - An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastati…
Merck Sharp & Dohme LLC - A randomized, open label phase 2/3 study comparing cobolimab + dostarl
GlaxoSmithKline, LLC. - A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations
E.r. Squibb & Sons, L.l.c. · Active, not recruiting · NCT06101134
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.